Life Sciences

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried […]

Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and the growth of Pace® Life Sciences over the past few years. https://www.youtube.com/watch?v=t_w6Re3vZbU

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The Changing Landscape of Gene Therapy, written by Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace® Life Sciences (PLS). Read the full article

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development

The installation and validation of our LabVantage Laboratory Information Management System (LIMS) is complete in our Philadelphia site!   Staff at our Philadelphia site worked together with cross-functional teams in Quality, Operations, IT, CSols, Inc. and LabVantage (vendor) to complete the installation and validation of a highly-functional and GMP compliant LIMS system. Lou Forcellini, site

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Drug Development and Delivery recently interviewed our very own, Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace Analytical® Life Sciences (PLS). After two recent acquisitions, Pace now operates five state-of-the-art facilities, and is well-equipped to handle almost any project regardless of scope or